PYPD Share Price Performance
US$3.65
0.10 (2.82%)
Price US$3.65
Share PriceUS$3.65
Is PolyPid (NASDAQ:PYPD) A Risky Investment?
Oct 28
PolyPid Ltd. Stock Price
- 0 Narratives written by author
- 0 Comments on narratives written by author
- 1 Fair Values set on narratives written by author
PYPD Community Narratives
There are no narratives available yet.
There are no community narratives available.
Snowflake Analysis
PolyPid Ltd. Key Details
Last Reported Earnings
Jun 30, 2025
Next Reporting Earnings
Nov 12, 2025
- -2.21
- 0%
- 0%
- 32.0%
About PYPD
- Founded
- 2008
- Employees
- 59
- CEO
- WebsiteView website
PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, which is in preclinical stage for the treatment of intra-tumoral cancer. The company has a research and development collaboration with ImmunoGenesis, Inc. for the development of formulations to treat solid tumors. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.
